

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) November 6, 2003

BECTON, DICKINSON AND COMPANY

(Exact name of registrant as specified in its charter)

<TABLE>

<S>	<C>	<C>
New Jersey	001-4802	22-0760120
(State or other juris- diction of incorporation)	(Commission File Number)	(IRS Employer Iden- tification Number)

1 Becton Drive, Franklin Lakes, New Jersey 07417-1880

(Address of principal executive offices) (Zip Code)
</TABLE>

Registrant's telephone number, including area code (201) 847-6800

N/A

(Former name or former addresses if changed since last report.)

Item 7. Financial Statements and Exhibits.

(c) Exhibits.

Exhibit 99.1 Press release dated November 6, 2003
announcing financial results for the fourth quarter
and fiscal year ended September 30, 2003.

Item 12. Results of Operations and Financial Condition.

On November 6, 2003, the Company issued a press release announcing
its financial results for the fourth quarter and fiscal year ended
September 30, 2003. A copy of the press release is furnished as
Exhibit 99.1 to this Current Report and is incorporated herein by
reference.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BECTON, DICKINSON AND COMPANY
(Registrant)

GARY DEFAZIO

By: /s/ Gary DeFazio

Gary DeFazio
Assistant Secretary

Date: November 6, 2003

2

INDEX TO EXHIBITS

<TABLE>
<CAPTION>

Exhibit Number -----	Description of Exhibits -----
<S> 99.1	<C> Press release issued November 6, 2003

</TABLE>

STATEMENT OF DIFFERENCES

The trademark symbol shall be expressed as.....'TM'

Contact:

- -----

Charles A. Borgognoni/Corporate Communications - 201-847-6651
Patricia A. Spinella/Investor Relations - 201-847-5453

BD ANNOUNCES RECORD FISCAL FOURTH QUARTER
AND FULL YEAR REVENUES

Franklin Lakes, NJ (November 6, 2003) - BD (Becton, Dickinson and Company) (NYSE: BDX) today reported record quarterly revenues of \$1.177 billion for the fiscal fourth quarter ended September 30, 2003, an increase of 9 percent from the same period a year ago. For the full year, the Company reported record revenues of \$4.528 billion, a 12 percent increase over a year ago. At constant foreign exchange rates, revenues increased 5 percent for the quarter and 8 percent for the fiscal year. Revenue growth in all segments benefited from favorable foreign currency translation, particularly with respect to the Euro, for the quarter and the year.

Diluted earnings per share and net income for the quarter were 61 cents and \$161 million, respectively. Diluted earnings per share and net income for the year were \$2.07 and \$547 million, respectively. Included in the full year results were non-cash charges recorded in the third quarter totaling 8 cents per share. These non-cash charges related to the write-down of certain intangible assets and inventory in the BD Biosciences segment. Excluding these charges, diluted earnings per share for the full year of fiscal 2003 would have been \$2.15.

Diluted earnings per share for the fourth quarter of fiscal year 2002 were 50 cents, which included a charge totaling 3 cents per share relating to the non-cash write-down of two equity investments resulting from a decline in market values. Excluding this charge, diluted earnings per share would have been 53 cents. In addition to the investment write-downs, diluted earnings per share for the full year of fiscal 2002 of \$1.79 also included special charges recorded in the second and third quarters totaling 6 cents per share, related to the manufacturing restructuring in the BD Medical segment. Excluding charges, diluted earnings per share for the full year of fiscal 2002 would have been \$1.88.

"We accelerated growth and improved our operating effectiveness during the past year by driving innovation and productivity. Revenue growth for the year was driven, in particular, by our broad line of safety-engineered products, prefillable devices, the BD ProbeTec ET™, and the BD FACSaria™, our state-of-the-art BD Biosciences instrument," said Edward J. Ludwig, Chairman, President and Chief Executive Officer. "Importantly, our investments in operational improvements worldwide are contributing to strong cash flow and higher gross profit margins. We are successfully implementing our strategy and we're seeing very tangible results."

Segment Results

- -----

In an effort to simplify and clarify the names of its business segments and units, the Company has announced the following changes, which became effective October 1, 2003. The three segment names are now BD Medical (formerly BD Medical Systems), BD Diagnostics (formerly BD Clinical Laboratory Solutions), and BD Biosciences (no change). Within BD Medical, unit name changes are Diabetes Care (formerly Consumer Healthcare), and Medical Surgical Systems (formerly Medical Surgical). Within BD Diagnostics, the only name change is Preanalytical Systems (formerly Preanalytical Solutions). Finally, within BD Biosciences, name changes are Immunocytometry Systems (formerly Flow Cytometry Instruments and Reagents), Clontech (formerly Molecular Biology Reagents), and Pharmingen (formerly Immunology/Cell Biology Reagents).

In the BD Medical segment, worldwide revenues of \$635 million increased 11 percent for the quarter. Included in these revenues were U.S. safety-engineered product sales of \$108 million, versus \$103 million in the prior year's quarter. U.S. sales of safety-engineered products for the full year totaled \$407 million, versus \$353 million in the prior year. The Pharmaceutical Systems unit contributed double-digit growth to the segment's results in the quarter and the full year. The overall growth rate in the segment for the quarter and the full year was partly offset by reduced sales of certain conventional devices in the U.S. due to the transition to safety-engineered devices.

In the BD Diagnostics segment, worldwide revenues increased 6 percent for the quarter to \$347 million. Revenue growth of 7 percent in the Preanalytical Systems unit was due primarily to U.S. safety-engineered product sales, which were \$74 million, versus \$64 million in the prior year's quarter. U.S. sales of safety-engineered products for the full year totaled \$273 million, versus \$220

million in the prior year. Also contributing to the segment's performance were worldwide sales of Diagnostic Systems products, which increased by 6 percent, driven in large part by solid performance of its molecular diagnostic platform, the BD ProbeTec ET™. The overall growth rate of the Preanalytical Systems unit was partly offset by reduced sales of certain conventional devices in the U.S. due to the transition to safety-engineered devices.

In the BD Biosciences segment, worldwide revenues grew 10 percent to \$195 million for the quarter. Revenue growth was driven by strong sales of the new BD FACSAria™ cell sorter, which BD Biosciences began shipping at the end of March 2003. This growth was offset in part by continued weak demand for certain Clontech reagents as well as a general slowdown in biotechnology research spending affecting our Pharmingen and Discovery Labware units.

Geographic Results

On a geographic basis, fourth quarter revenues in the U.S. increased 4 percent to \$610 million. Revenues outside the U.S. of \$567 million grew 15 percent, or 6 percent at constant foreign exchange rates. For the full year, revenues in the U.S. increased 8 percent to \$2.328 billion. Revenues of \$2.2 billion outside the U.S. increased by 17 percent, or 8 percent at constant foreign exchange rates.

Fiscal 2004 Outlook

The Company estimates diluted earnings per share for fiscal 2004 will increase in the range of 10-12 percent, based on fiscal 2003 earnings per share of \$2.15, which excludes non-cash charges as previously discussed. The Company estimates that first quarter diluted earnings per share will increase approximately 8-10 percent, based on fiscal first quarter 2003 diluted earnings per share of \$0.43, reflecting the timing of investment spending on the blood glucose monitoring initiative.

Conference Call Information

A conference call regarding BD's fourth quarter results and its expectations for the first quarter will be broadcast live on BD's website www.bd.com/investors at 8:30 a.m. (ET) Thursday, November 6, 2003. The conference call will be available for replay on BD's website www.bd.com/investors or at 1-888-566-0450 (domestic) and 1-402-998-0620 (international) through the close of business on November 13, 2003.

This news release contains certain non-GAAP financial measures. A reconciliation of these measures to the comparable GAAP measures is included in this release and in the attached financial tables.

BD is a medical technology company that serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public. BD manufactures and sells a broad range of medical supplies, devices, laboratory equipment and diagnostic products. For the fiscal year ended September 30, 2003, BD reported total revenues of \$4.528 billion

This press release may contain certain forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues, products and income, or events or developments that BD expects to occur or anticipates occurring in the future. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. Factors that could cause actual results to vary materially from any forward-looking statement include, but are not limited to: competitive factors; pricing and market share pressures; uncertainties of litigation; BD's ability to achieve sales and earnings forecasts, which are based on sales volume and product mix assumptions, to achieve its cost savings objectives, and to achieve anticipated synergies and other cost savings in connection with acquisitions; changes in regional, national or foreign economic conditions; increases in energy costs; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; changes in interest or foreign currency exchange rates; delays in product introductions; and changes in health care or other governmental regulation, as well as other factors discussed in this press release and in BD's filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements.

BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in thousands, except per-share data)

<TABLE>
<CAPTION>

	Three Months Ended September 30,		
	2003	2002	% Change
<S>	<C>	<C>	<C>
REVENUES	\$1,176,882	\$1,076,692	9.3
Cost of products sold	585,436	546,703	7.1
Selling and administrative	316,010	282,232	12.0
Research and development	55,139	55,598	(0.8)
TOTAL OPERATING COSTS AND EXPENSES	956,585	884,533	8.1
OPERATING INCOME	220,297	192,159	14.6
Interest expense, net	(9,616)	(6,216)	54.7
Other income (expense), net	939	(13,959)	NM
INCOME BEFORE INCOME TAXES	211,620	171,984	23.0
Income tax provision	50,260	40,588	23.8
NET INCOME	\$ 161,360	\$ 131,396	22.8
EARNINGS PER SHARE			
Basic	\$ 0.64	\$ 0.51	25.5
Diluted	\$ 0.61	\$ 0.50	22.0
AVERAGE SHARES OUTSTANDING			
Basic	252,983	256,376	
Diluted	262,601	264,091	

</TABLE>

NM - Not Meaningful

Page 1

BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in thousands, except per-share data)

<TABLE>
<CAPTION>

	Twelve Months Ended September 30,		
	2003	2002	% Change
<S>	<C>	<C>	<C>
REVENUES	\$4,527,940	\$4,033,069	12.3
Cost of products sold	2,336,290 *	2,083,669	12.1
Selling and administrative	1,207,464	1,032,043	17.0
Research and development	235,060	220,186	6.8
Special charges	-	21,508	NM
TOTAL OPERATING COSTS AND EXPENSES	3,778,814	3,357,406	12.6
OPERATING INCOME	749,126	675,663	10.9
Interest expense, net	(36,560)	(33,304)	9.8
Other (expense) income, net	(2,860)	(13,770)	NM

INCOME BEFORE INCOME TAXES	709,706	628,589	12.9
Income tax provision	162,650	148,607	9.4
NET INCOME	\$ 547,056	\$ 479,982	14.0
EARNINGS PER SHARE			
Basic	\$ 2.14	\$ 1.85	15.7
Diluted	\$ 2.07	\$ 1.79	15.6
AVERAGE SHARES OUTSTANDING			
Basic	254,497	258,016	
Diluted	263,635	268,183	

</TABLE>

NM - Not Meaningful

* Includes \$34,231 of non-cash charges, as more fully described on page 3.

Page 2

BECTON DICKINSON AND COMPANY
RECONCILIATION TO PRO FORMA AMOUNTS
Periods Ended September 30,
(Unaudited; Amounts in thousands, except per-share data)

<TABLE>
<CAPTION>

	For the three months ended September 30,			
	As Reported	Non-cash Charges	Special Charges	Excluding Charges
<S> 2003	<C>	<C>	<C>	<C>
Diluted EPS	\$0.61	\$ -	\$ -	\$0.61
2002				
Diluted EPS	\$0.50	\$0.03 {a}	\$ -	\$0.53

</TABLE>

<TABLE>
<CAPTION>

	For the twelve months ended September 30,			
	As Reported	Non-cash Charges	Special Charges	Excluding Charges
<S> 2003	<C>	<C>	<C>	<C>
Gross Profit as a % of revenues	\$2,191,650 48.4%	\$34,231	\$ -	\$2,225,881 49.2%
Diluted EPS	\$ 2.07	\$ 0.08{b}	\$ -	\$ 2.15
2002				
Diluted EPS	\$ 1.79	\$ 0.03{a}	\$0.06{c}	\$ 1.88

</TABLE>

{a} Relates to the fiscal 2002 non-cash write-down of two equity investments resulting from a decline in market values.

{b} Relates to the fiscal 2003 write-down of certain intangible assets and inventory in the BD Biosciences segment.

{c} Relates to the fiscal 2002 manufacturing restructuring in the BD Medical segment.

BECTON DICKINSON AND COMPANY
 SUPPLEMENTAL REVENUE INFORMATION
 REVENUES BY SEGMENT AND GEOGRAPHIC AREA
 (Unaudited; Amounts in thousands)

<TABLE>
 <CAPTION>

	Three Months Ended September 30,		
	2003	2002	% Change
<S>	<C>	<C>	<C>
BD MEDICAL			
United States	\$ 316,701	\$ 300,433	5.4
International	318,291	273,351	16.4
TOTAL	\$ 634,992	\$ 573,784	10.7
BD DIAGNOSTICS			
United States	\$ 197,111	\$ 194,747	1.2
International	149,903	131,136	14.3
TOTAL	\$ 347,014	\$ 325,883	6.5
BD BIOSCIENCES			
United States	\$ 96,506	\$ 90,530 *	6.6
International	98,370	86,495 *	13.7
TOTAL	\$ 194,876	\$ 177,025	10.1
TOTAL REVENUES			
United States	\$ 610,318	\$ 585,710 *	4.2
International	566,564	490,982 *	15.4
TOTAL	\$1,176,882	\$1,076,692	9.3

</TABLE>

* Prior year data reclassified to conform to current year presentation.

BECTON DICKINSON AND COMPANY
 SUPPLEMENTAL REVENUE INFORMATION
 REVENUES BY SEGMENT AND GEOGRAPHIC AREA
 (Unaudited; Amounts in thousands)

<TABLE>
 <CAPTION>

	Twelve Months Ended September 30,		
	2003	2002	% Change
<S>	<C>	<C>	<C>
BD MEDICAL			
United States	\$1,211,957	\$1,092,428	10.9
International	1,244,919	1,058,946	17.6
TOTAL	\$2,456,876	\$2,151,374	14.2
BD DIAGNOSTICS			
United States	\$ 785,737	\$ 735,613	6.8
International	587,914	500,706	17.4

TOTAL	\$1,373,651	\$1,236,319	11.1
BD BIOSCIENCES			
United States	\$ 330,552	\$ 330,234 *	0.1
International	366,861	315,142 *	16.4
TOTAL	\$ 697,413	\$ 645,376	8.1
TOTAL REVENUES			
United States	\$2,328,246	\$2,158,275 *	7.9
International	2,199,694	1,874,794 *	17.3
TOTAL	\$4,527,940	\$4,033,069	12.3

</TABLE>

* Prior year data reclassified to conform to current year presentation

Page 5

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended September 30,
(Unaudited; Amounts in thousands)

<TABLE>
<CAPTION>

	United States		
	2003	2002	% Change
<S>	<C>	<C>	<C>
BD MEDICAL			
Medical Surgical Systems	\$195,314	\$195,183 *	0.1
Diabetes Care	95,129	79,452 *	19.7
Pharmaceutical Systems	21,071	20,295	3.8
Ophthalmic Systems	5,187	5,503	(5.7)
TOTAL	\$316,701	\$300,433	5.4
BD DIAGNOSTICS			
Preanalytical Systems	\$107,420	\$106,364	1.0
Diagnostic Systems	89,691	88,383	1.5
TOTAL	\$197,111	\$194,747	1.2
BD BIOSCIENCES			
Discovery Labware	\$ 26,210	\$ 27,050	(3.1)
Immunocytometry Systems	44,722	36,249	23.4
Clontech	7,575	8,916 *	(15.0)
Pharming	17,999	18,315	(1.7)
TOTAL	\$ 96,506	\$ 90,530 *	6.6
TOTAL UNITED STATES	\$610,318	\$585,710 *	4.2

</TABLE>

* Prior year data reclassified to conform to current year presentation

Page 6

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended September 30, (continued)
(Unaudited; Amounts in thousands)

<TABLE>
<CAPTION>

	International				
			% Change		FX Impact
	2003	2002	Reported	FX Neutral	
<S>	<C>	<C>	<C>	<C>	<C>
BD MEDICAL					
Medical Surgical Systems	\$173,597	\$153,184	13.3	5.3	8.0
Diabetes Care	56,707	48,236	17.6	7.5	10.1
Pharmaceutical Systems	80,154	64,448	24.4	11.3	13.1
Ophthalmic Systems	7,833	7,483	4.7	(3.1)	7.8
TOTAL	\$318,291	\$273,351	16.4	6.9	9.5
BD DIAGNOSTICS					
Preanalytical Systems	\$ 76,027	\$ 64,910	17.1	7.2	9.9
Diagnostic Systems	73,876	66,226	11.6	3.9	7.7
TOTAL	\$149,903	\$131,136	14.3	5.6	8.7
BD BIOSCIENCES					
Discovery Labware	\$ 21,303	\$ 18,662	14.2	7.1	7.1
Immunocytometry Systems	56,170	46,787	20.1	10.4	9.7
Clontech	7,883	9,127 *	(13.6)	(17.8)	4.2
Pharminggen	13,014	11,919	9.2	(0.2)	9.4
TOTAL	\$ 98,370	\$ 86,495 *	13.7	5.2	8.5
TOTAL INTERNATIONAL	\$566,564	\$490,982 *	15.4	6.2	9.2

* Prior year data reclassified to conform to current year presentation

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended September 30, (continued)
(Unaudited; Amounts in thousands)

<TABLE>
<CAPTION>

	Total				
			% Change		FX Impact
	2003	2002	Reported	FX Neutral	
<S>	<C>	<C>	<C>	<C>	<C>
BD MEDICAL					
Medical Surgical Systems	\$ 368,911	\$ 348,367 *	5.9	2.4	3.5
Diabetes Care	151,836	127,688 *	18.9	15.1	3.8
Pharmaceutical Systems	101,225	84,743	19.4	9.5	9.9

Ophthalmic Systems	13,020	12,986	0.3	(4.2)	4.5
TOTAL	\$ 634,992	\$ 573,784	10.7	6.1	4.6
BD DIAGNOSTICS					
Preanalytical Systems	\$ 183,447	\$ 171,274	7.1	3.4	3.7
Diagnostic Systems	163,567	154,609	5.8	2.5	3.3
TOTAL	\$ 347,014	\$ 325,883	6.5	3.0	3.5
BD BIOSCIENCES					
Discovery Labware	\$ 47,513	\$ 45,712	3.9	1.1	2.8
Immunocytometry Systems	100,892	83,036	21.5	16.1	5.4
Clontech	15,458	18,043	(14.3)	(16.4)	2.1
Pharmingen	31,013	30,234	2.6	(1.1)	3.7
TOTAL	\$ 194,876	\$ 177,025	10.1	5.9	4.2
TOTAL REVENUES	\$1,176,882	\$1,076,692	9.3	5.1	4.2

</TABLE>

* Prior year data reclassified to conform to current year presentation

Page 8

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Twelve Months Ended September 30,
(Unaudited; Amounts in thousands)

<TABLE>
<CAPTION>

	United States		
	2003	2002	% Change
<S>	<C>	<C>	<C>
BD MEDICAL			
Medical Surgical Systems	\$ 759,627	\$ 707,447 *	7.4
Diabetes Care	335,612	288,789 *	16.2
Pharmaceutical Systems	93,422	71,122	31.4
Ophthalmic Systems	23,296	25,070	(7.1)
TOTAL	\$1,211,957	\$1,092,428	10.9
BD DIAGNOSTICS			
Preanalytical Systems	\$ 414,270	\$ 383,482	8.0
Diagnostic Systems	371,467	352,131	5.5
TOTAL	\$ 785,737	\$ 735,613	6.8
BD BIOSCIENCES			
Discovery Labware	\$ 97,609	\$ 99,595	(2.0)
Immunocytometry Systems	132,022	124,327	6.2
Clontech	31,928	39,584 *	(19.3)
Pharmingen	68,993	66,728	3.4
TOTAL	\$ 330,552	\$ 330,234 *	0.1
TOTAL UNITED STATES	\$2,328,246	\$2,158,275 *	7.9

</TABLE>

* Prior year data reclassified to conform to current year presentation

Page 9

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Twelve Months Ended September 30, (continued)
(Unaudited; Amounts in thousands)

<TABLE>
<CAPTION>

	International				
			% Change		FX Impact
	2003	2002	Reported	FX Neutral	
<S>	<C>	<C>	<C>	<C>	<C>
BD MEDICAL					
Medical Surgical Systems	\$ 666,575	\$ 591,782	12.6	6.4	6.2
Diabetes Care	206,715	185,036	11.7	2.9	8.8
Pharmaceutical Systems	342,202	255,224	34.1	17.6	16.5
Ophthalmic Systems	29,427	26,904	9.4	(1.2)	10.6
TOTAL	\$1,244,919	\$1,058,946	17.6	8.3	9.3
BD DIAGNOSTICS					
Preanalytical Systems	\$ 292,809	\$ 253,712	15.4	5.6	9.8
Diagnostic Systems	295,105	246,994	19.5	10.9	8.6
TOTAL	\$ 587,914	\$ 500,706	17.4	8.2	9.2
BD BIOSCIENCES					
Discovery Labware	\$ 81,814	\$ 68,228	19.9	10.2	9.7
Immunocytometry Systems	200,483	170,391	17.7	6.2	11.5
Clontech	32,384	33,126 *	(2.2)	(9.8)	7.6
Pharmingen	52,180	43,397	20.2	8.3	11.9
TOTAL	\$ 366,861	\$ 315,142 *	16.4	5.7	10.7
TOTAL INTERNATIONAL	\$2,199,694	\$1,874,794 *	17.3	7.8	9.5

</TABLE>

* Prior year data reclassified to conform to current year presentation

Page 10

Twelve Months Ended September 30, (continued)
(Unaudited; Amounts in thousands)

<TABLE>
<CAPTION>

	Total				
			% Change		FX Impact
	2003	2002	Reported	FX Neutral	
<C>	<C>	<C>	<C>	<C>	
BD MEDICAL					
Medical Surgical Systems	\$1,426,202	\$1,299,229 *	9.8	6.9	2.9
Diabetes Care	542,327	473,825 *	14.5	11.0	3.5
Pharmaceutical Systems	435,624	326,346	33.5	20.6	12.9
Ophthalmic Systems	52,723	51,974	1.4	(4.0)	5.4
TOTAL	\$2,456,876	\$2,151,374	14.2	9.6	4.6
BD DIAGNOSTICS					
Preanalytical Systems	\$ 707,079	\$ 637,194	11.0	7.0	4.0
Diagnostic Systems	666,572	599,125	11.3	7.7	3.6
TOTAL	\$1,373,651	\$1,236,319	11.1	7.4	3.7
BD BIOSCIENCES					
Discovery Labware	\$ 179,423	\$ 167,823	6.9	3.0	3.9
Immunocytometry Systems	332,505	294,718	12.8	6.2	6.6
Clontech	64,312	72,710	(11.5)	(15.0)	3.5
Pharmingen	121,173	110,125	10.0	5.3	4.7
TOTAL	\$ 697,413	\$ 645,376	8.1	2.8	5.3
TOTAL REVENUES	\$4,527,940	\$4,033,069	12.3	7.8	4.5

</TABLE>

* Prior year data reclassified to conform to current year presentation